Plain-English translation of NCT06766825 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 clinical trial testing a medication called plitidepsin in adults with long COVID—the condition where symptoms like fatigue, breathing problems, and brain fog continue for months after an initial COVID-19 infection. The medication works in three ways: it targets leftover viral particles, reduces inflammation in the body, and may prevent certain viruses from reactivating. About 90 people will be randomly assigned to receive either the medication, a placebo (a dummy infusion), or a combination of both over the course of several months.
Long COVID affects millions of people worldwide, and there are currently no proven treatments to help them recover. This medication has shown promise in early laboratory studies, so researchers want to see if it can safely reduce long COVID symptoms and improve quality of life in real patients.
You would come to the clinic for four separate treatment periods over about 3 months. During each period, you would receive intravenous infusions (through a needle in your vein) over 1 hour on three consecutive days. Depending on which group you're randomly assigned to, you may receive the actual medication, placebo infusions only, or a combination of both. The study team will monitor you closely for side effects and improvements in your symptoms throughout the trial.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
Spain